Loading stock…

LifeStance Health Group, Inc. (LFST) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

LifeStance Health Group, Inc.

LFSTMarket cap $4.63BPrice $12.1

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

LifeStance runs one of the largest networks of outpatient mental health clinics in the US, with hundreds of centers staffed by thousands of clinicians. Demand for therapy keeps outpacing supply, and this company is scaling to fill that gap.

In Bastion Portfolios?

52W Return+140%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+18%9

Revenue Forecast

Rev CAGR (1y)+20%8

Rev CAGR (3y)+16%8

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+1357%10

EPS Growth Y+2+18%8

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin5%3

Net Income Margin3%3

Free Cash Flow Margin11%6

Debt

Net Debt/EBITDA1.35

Efficiency

ROE3%3

ROA2%4

Earnings Stability44

GEAR+AVERAGE38

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)312

P/E Ratio (Forward 3y)232

P/BV3.15

EV Multiples

EV/EBITDA Fwd212

EV/EBIT Fwd511

Yield

Free Cash Flow Yield3.8%5

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return+11%9

YTD return+72%10

Mid term

Price vs 52wHigh89%8

1 year return+119%10

Long term

3 year return+83%7

5 year return-8%3

Risk Shield

Price Risk

Beta0.76

Volatility50%3

Free Cash Flow

Free Cash Flow Margin11%6

Free Cash Flow Yield3.8%5

Quality

ROCE4%3

Earnings Stability44

Net Debt/EBITDA1.35

02Growth

Is it actually growing, and how fast?

LFSTLifeStance Health Group

Revenue FY25$1.4B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+20%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+1357%10

EPS growth, FY27E+18%8

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 18%/yr over the last 3 years and is set to keep growing around 16%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 23%/yr vs revenue 16%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG76 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+11%9

YTD return+72%10

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+119%10

3-year return+83%7

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 119% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+11%) and so far this year (+72%).

WATCH

Average long-term results. Multi-year returns are middling (+83% over three years and -7.8% over five), roughly average for the market.

Returns sit at the market level over the past month (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on LifeStance Health Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LFSTLifeStance Health Group

Revenue FY25$1.4B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+20%8

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+1357%10

EPS growth, FY27E+18%8

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 18%/yr over the last 3 years and is set to keep growing around 16%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 23%/yr vs revenue 16%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG76 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+11%9

YTD return+72%10

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+119%10

3-year return+83%7

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 119% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+11%) and so far this year (+72%).

WATCH

Average long-term results. Multi-year returns are middling (+83% over three years and -7.8% over five), roughly average for the market.

Returns sit at the market level over the past month (-5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on LifeStance Health Group, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community